The National Institutes of Health (NIH) is offering a grant to support the development and evaluation of host-directed therapies for Mycobacterium tuberculosis (TB) treatment in the context of HIV co-infection. This grant aims to advance research on therapies that are already approved for clinical use or in late-stage trials for other conditions. The funding, provided through the UH2/UH3 mechanism, will first support preclinical data development and partnership building, followed by funding for proof-of-concept clinical trials. Applications must align with the objectives outlined in the Funding Opportunity Announcement before the closing date on March 25, 2015.
Opportunity ID: 269528
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AI-14-058 |
| Funding Opportunity Title: | Host-Directed TB Therapy: New Approaches (UH2/UH3) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.855 — Allergy, Immunology and Transplantation Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 12, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Mar 25, 2015 |
| Current Closing Date for Applications: | Mar 25, 2015 |
| Archive Date: | Apr 25, 2015 |
| Estimated Total Program Funding: | $2,900,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments Independent school districts Public housing authorities/Indian housing authorities Private institutions of higher education Public and State controlled institutions of higher education Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Native American tribal governments (Federally recognized) City or township governments For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for support of preclinical evaluation, planning for and conduct of proof-of-concept clinical studies for Mycobacterium tuberculosis (TB) treatment that will be applicable in the context of HIV co-infection using host-directed agents already approved for clinical use or in late-stage clinical trials for other conditions. Host-directed therapies (HDT) for TB that may also have activity against HIV, either directly or by enhancing immunologic reactions, are of particular interest.
Funds from the NIH will be made available through the UH2/UH3 cooperative agreement award mechanism. The initial UH2 award (up to two years) will support the development of critical preclinical data, development of study partnerships, and development of the proof-of-concept (POC) trial protocol and all supporting plans and documentation. Once UH2 pre-clinical and clinical milestones have been met, the UH3 award (up to 3 years) may be made to support the planned POC clinical trial. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-058.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-C | FORMS-C | PKG00209823 | Feb 25, 2015 | Mar 25, 2015 | View |
Package 1
Mandatory forms
269528 RR_SF424_2_0-2.0.pdf
269528 PHS398_ResearchPlan_2_0-2.0.pdf
269528 PHS398_CoverPageSupplement_2_0-2.0.pdf
269528 RR_Budget_1_3-1.3.pdf
269528 RR_KeyPersonExpanded_2_0-2.0.pdf
269528 RR_OtherProjectInfo_1_3-1.3.pdf
269528 PerformanceSite_2_0-2.0.pdf
Optional forms
269528 PlannedReport-1.0.pdf
269528 PHS398_CumulativeInclusionReport-1.0.pdf
269528 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
